Harm/ risk (analysis)

Latest Articles

Article
Thromboembolic risk with IVIgIncidence and risk factors in patients with inflammatory neuropathy
Mahima Kapoor, Jennifer Spillane, Christina Englezou, et al.

Neurology December 18, 2019
Article
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Lana Zhovtis Ryerson, John Foley, Ih Chang, et al.

Neurology September 12, 2019
Editorial
Dosing interval of natalizumab in MSDo good things come to those who wait?
David B. Clifford, Kenneth L. Tyler

Neurology September 12, 2019
Article
Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA
Caty Carrera, Natalia Cullell, Nuria Torres-Águila, et al.

Neurology July 31, 2019